register

News & Trends - Pharmaceuticals

Roche extends add-on evidence in breast cancer

Health Industry Hub | February 19, 2021 |

Pharma News: Findings from 6 years median follow-up in the APHINITY study confirm benefit in invasive disease-free survival (IDFS) from adding Roche’s Perjeta (pertuzumab) to standard adjuvant treatment in patients with node-positive, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

The authors concluded that the second interim analysis of OS in the APHINITY study did not demonstrate a statistically significant OS benefit from adding Perjeta (pertuzumab) to standard chemotherapy plus Herceptin (trastuzumab) in HER2-positive early-stage breast cancer (p = 0.17); the number of OS events still remains relatively low.

The benefits of dual HER2 blockade using Perjeta (pertuzumab) and trastuzumab in the adjuvant setting for patients with node-positive disease observed at the primary analysis are reinforced in the updated analysis of IDFS. There is no evidence to justify the routine use of adjuvant dual anti-HER2 treatment for patients with node-negative early breast cancer.

Informa Telehealth Summit - Health Industry Hub supporting partner

Cardiac safety was confirmed with primary cardiac events remain <1% in both treatment groups.

The authors underlined that continued follow-up of patients is important to fully assess OS benefit at the time-driven third interim OS analysis planned for 2022.

To directly combat launch of biosimilar Herceptin, Roche in mid-2020 launched Phesgo, a fixed-dose combination of Herceptin and Perjeta, for HER2-positive breast cancer. The single-dose vial can be given in a treatment centre or at home, offering patients significant convenience. Previously, the two drugs had to be given separately. Phesgo is currently approved by the FDA and EMA, and awaiting TGA approval.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.